mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 23, Issue 10, Pages 2526-2535
Publisher
Oxford University Press (OUP)
Online
2012-05-03
DOI
10.1093/annonc/mds075
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- S3-7: Everolimus for Postmenopausal Women with Advanced Breast Cancer: Updated Results of the BOLERO-2 Phase III Trial.
- (2012) GN Hortobagyi et al. CANCER RESEARCH
- Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2011) S. Aebi et al. ANNALS OF ONCOLOGY
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
- (2011) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- Everolimus in Combination with Exemestane for Postmenopausal Women with Advanced Breast Cancer Who Are Refractory to Letrozole or Anastrozole: Results of the BOLERO-2 Phase III Trial
- (2011) J. Baselqa et al. EUROPEAN JOURNAL OF CANCER
- Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma
- (2011) Camillo Porta et al. EUROPEAN JOURNAL OF CANCER
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms of Endocrine Resistance in Breast Cancer
- (2010) C. Kent Osborne et al. Annual Review of Medicine
- The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study
- (2010) E. J. Macaskill et al. BREAST CANCER RESEARCH AND TREATMENT
- “Overcoming breast cancer drug resistance with mTOR inhibitors”. Could it be a myth or a real possibility in the short-term future?
- (2010) Nadia Margariti et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase 3 trial of everolimus for metastatic renal cell carcinoma
- (2010) Robert J. Motzer et al. CANCER
- Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer
- (2010) Angelo Di Leo et al. JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer
- (2010) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009
- (2009) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163
- (2009) Susan L. Ellard et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer
- (2009) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen
- (2009) Mitch Dowsett et al. JOURNAL OF CLINICAL ONCOLOGY
- Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen
- (2008) Hagen Kennecke et al. CANCER
- Endocrine therapy of metastatic breast cancer
- (2008) Laura Rodríguez Lajusticia et al. Clinical & Translational Oncology
- Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
- (2008) Grazia Arpino et al. ENDOCRINE REVIEWS
- Targeted therapies in breast cancer: Where are we now?
- (2008) Serena Di Cosimo et al. EUROPEAN JOURNAL OF CANCER
- Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation?
- (2008) P.E. Lønning EUROPEAN JOURNAL OF CANCER
- Advances in Adjuvant Endocrine Therapy for Postmenopausal Women
- (2008) Nancy U. Lin et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study Comparing Exemestane With Tamoxifen As First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group
- (2008) Robert J. Paridaens et al. JOURNAL OF CLINICAL ONCOLOGY
- Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT
- (2008) Stephen Chia et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now